SEQUENT WEEKLY long after breakout
已更新
View is mine money is yours DYOR before investing or trading
expecting a bullish view in SEQUENT
About
Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries.
Market Cap ₹ 3,533 Cr.
Current Price ₹ 142
High / Low ₹ 156 / 86.0
Stock P/E
Book Value ₹ 26.3
Dividend Yield 0.00 %
ROCE 0.90 %
ROE -2.46 %
Face Value ₹ 2.00
Promoter holding 52.8 %
Change in Prom Hold -0.01 %
Sales growth -3.60 %
Profit growth 73.3 %
Dividend yield 0.00 %
Current ratio 1.31
Profit after tax ₹ -16.7 Cr.
Price to book value 5.38
Sales ₹ 1,370 Cr.
Sales Qtr ₹ 361 Cr.
Qtr Sales Var -1.49 %
Qtr Profit Var 107 %
EVEBITDA 54.6
Return over 3months 13.3 %
Price to Earning
ROCE 0.90 %
Debt ₹ 488 Cr.
Return on equity -2.46 %
Cons
- Stock is trading at 5.38 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 5.68% over past five years.
- Company has a low return on equity of -1.84% over last 3 years.
- Can long after breakout expecting a quick move to 1st target
- cup and handle pattern
- DIIs increased their holding stake
Compounded Sales Growth
10 Years: 13%
5 Years: 6%
3 Years: 0%
TTM: -4%
Compounded Profit Growth
10 Years: 5%
5 Years: %
3 Years: %
TTM: 73%
Stock Price CAGR
10 Years: 7%
5 Years: 15%
3 Years: -22%
1 Year: 58%
Return on Equity
10 Years: 9%
5 Years: 4%
3 Years: -2%
Last Year: -2%
expecting a bullish view in SEQUENT
About
Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries.
Market Cap ₹ 3,533 Cr.
Current Price ₹ 142
High / Low ₹ 156 / 86.0
Stock P/E
Book Value ₹ 26.3
Dividend Yield 0.00 %
ROCE 0.90 %
ROE -2.46 %
Face Value ₹ 2.00
Promoter holding 52.8 %
Change in Prom Hold -0.01 %
Sales growth -3.60 %
Profit growth 73.3 %
Dividend yield 0.00 %
Current ratio 1.31
Profit after tax ₹ -16.7 Cr.
Price to book value 5.38
Sales ₹ 1,370 Cr.
Sales Qtr ₹ 361 Cr.
Qtr Sales Var -1.49 %
Qtr Profit Var 107 %
EVEBITDA 54.6
Return over 3months 13.3 %
Price to Earning
ROCE 0.90 %
Debt ₹ 488 Cr.
Return on equity -2.46 %
Cons
- Stock is trading at 5.38 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 5.68% over past five years.
- Company has a low return on equity of -1.84% over last 3 years.
- Can long after breakout expecting a quick move to 1st target
- cup and handle pattern
- DIIs increased their holding stake
Compounded Sales Growth
10 Years: 13%
5 Years: 6%
3 Years: 0%
TTM: -4%
Compounded Profit Growth
10 Years: 5%
5 Years: %
3 Years: %
TTM: 73%
Stock Price CAGR
10 Years: 7%
5 Years: 15%
3 Years: -22%
1 Year: 58%
Return on Equity
10 Years: 9%
5 Years: 4%
3 Years: -2%
Last Year: -2%
交易开始
bought @140交易开始
BREKOUT, Good volume and momentum still a buy zone
upper circuit move possible in next week
交易结束：到达目标
3rd target hit 25% from my buy zone
still holding the trade full quantity
注释
next target : 202 ,225 ,240注释
TSL to 140注释
short term target hit all 3交易结束：到达目标
50% move from my entry exited half quantity holding other half with a tailed stoploss
交易开始
16% move today as i said 交易结束：到达目标
almost 70% from my entry , within 2 month
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。